Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 161 of the 164 references it cites were found in a registry or an index.

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Open access

Abstract

Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia. However, the activity of glucagonlike peptide 1 receptor–directed strategies is submaximal, and the only potent, sustainable treatment of metabolic dysfunction is bariatric surgery, necessitating the development of unique therapeutics. GLP-1 is structurally related to glucagon and glucose-dependent insulinotropic peptide (GIP), allowing for the development of intermixed, unimolecular peptides with activity at each of their respective receptors. In this review, we discuss the range of tissue targets and added benefits afforded by the inclusion of each of GIP and glucagon. We discuss considerations for the development of sequence-intermixed dual agonists and triagonists, highlighting the importance of evaluating balanced signaling at the targeted receptors. Several multireceptor agonist peptides have been developed and evaluated, and the key preclinical and clinical findings are reviewed in detail. The biological activity of these multireceptor agonists are founded in the success of GLP-1-directed strategies; by including GIP and glucagon components, these multireceptor agonists are thought to enhance GLP-1’s activities by broadening the tissue targets and synergizing at tissues that express multiple receptors, such at the brain and pancreatic isletβ cells. The development and utility of balanced, unimolecular multireceptor agonists provide both a useful tool for querying the actions of incretins and glucagon during metabolic disease and a unique drug class to treat type 2 diabetes with unprecedented efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2018-00117

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Glucagon, GLP-1, and GIP have unique activities at different tissue beds. Blue arrows show the effects of glucagon, green arrows show GLP-1 effects, and red arrows show GIP effects. Although there are overlapping activities of these peptides in the brain and pancreas, the majority of tissues have nonoverlapping receptor expression, yielding unique activities of each peptide at different tissues. Therefore, multireceptor agonists demonstrate additive effects, in part, by engaging a broader range of activities.
Figure 1. Glucagon, GLP-1, and GIP have unique activities at different tissue beds. Blue arrows show the effects of glucagon, green arrows show GLP-1 effects, and red arrows show GIP effects. Although there are overlapping activities of these peptides in the brain and pancreas, the majority of tissues have nonoverlapping receptor expression, yielding unique activities of each peptide at different tissues. Therefore, multireceptor agonists demonstrate additive effects, in part, by engaging a broader range of activities.CC BY-NC · PubMed Central
Figure 2. Proposed activities of GIPR antagonism vs agonism. The projected activities of a GIPR antagonist at each tissue with GIPR expression is shown in red, and agonism is shown in blue. References supporting these activities are provided in brackets. Italicized text indicates a presumed effect of agonism or antagonism but does not have data to support a known activity. ATBF, adipose tissue blood flow; TAG, triacylglycerol.
Figure 2. Proposed activities of GIPR antagonism vs agonism. The projected activities of a GIPR antagonist at each tissue with GIPR expression is shown in red, and agonism is shown in blue. References supporting these activities are provided in brackets. Italicized text indicates a presumed effect of agonism or antagonism but does not have data to support a known activity. ATBF, adipose tissue blood flow; TAG, triacylglycerol.CC BY-NC · PubMed Central
Figure 3. Design considerations of triagonists. (a) Each receptor (GLP-1R, blue; GCGR, red; GIPR, green) responds to its respective ligand. (b) A balanced fusion structure uses each individual peptide to provide recognition at all receptors. (c) A balanced hybrid peptide is a sequence-hybridized molecule of comparable size to the native peptides with equipotent activities at all receptors. (d) An unbalanced hybrid peptide is a sequence-intermixed molecule that preferentially activates certain receptors with higher affinity than others.
Figure 3. Design considerations of triagonists. (a) Each receptor (GLP-1R, blue; GCGR, red; GIPR, green) responds to its respective ligand. (b) A balanced fusion structure uses each individual peptide to provide recognition at all receptors. (c) A balanced hybrid peptide is a sequence-hybridized molecule of comparable size to the native peptides with equipotent activities at all receptors. (d) An unbalanced hybrid peptide is a sequence-intermixed molecule that preferentially activates certain receptors with higher affinity than others.CC BY-NC · PubMed Central
Figure 4. Two hypothesized models of synergism forβ-cell insulin secretion. (a) According to the cell heterogeneity model, unique populations ofβ cells exist that do not express all three incretin/glucagon receptors. In this model, the triagonist increases insulin secretion compared with a monoagonist by engaging multipleβ-cell subgroups to stimulate insulin secretion. (b) In the intracellular amplification model,β cells express all incretin/glucagon receptors, and the synergistic activity of the triagonist compared with the monoagonist is based on the crosstalk of downstream signaling cascades within an individualβ cell.
Figure 4. Two hypothesized models of synergism forβ-cell insulin secretion. (a) According to the cell heterogeneity model, unique populations ofβ cells exist that do not express all three incretin/glucagon receptors. In this model, the triagonist increases insulin secretion compared with a monoagonist by engaging multipleβ-cell subgroups to stimulate insulin secretion. (b) In the intracellular amplification model,β cells express all incretin/glucagon receptors, and the synergistic activity of the triagonist compared with the monoagonist is based on the crosstalk of downstream signaling cascades within an individualβ cell.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 164 references

Cited by

See all 153

Metadata

Authors
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E.
Affiliations
  • Duke University (US)
  • Indiana University Bloomington (US)
  • Helmholtz Munich (DE)
  • Novo Nordisk Research Center, Indianapolis, Indiana
Corresponding author
Campbell, Jonathan E
Venue
Endocrine Reviews
Published
2018-06-13
Volume
39
Issue
5
Pages
719-738
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2808030638
Cited by
153
References
164
Citations by year
2026: 10 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 19 · 2021: 30 · 2020: 24 · 2019: 25 · 2018: 4
FWCI
3.19
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Funders
  • NIH
  • American Diabetes Association (1-18-JDF-017)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, GLP-1 receptor agonists, glucagon, glucose-dependent insulinotropic polypeptide, incretin system, dual receptor agonist, pancreatic beta cells, brain, drug development, hyperglycemia
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. https://app.cochat.ai/papers/10.1210/er.2018-00117
The paper
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018). Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. Endocrine Reviews. https://doi.org/10.1210/er.2018-00117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.